Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–6 of 6 results
Advanced filters: Author: Gatien Moriceau Clear advanced filters

  • B-RAF is mutated in a large proportion of melanomas, and the first small molecule inhibitor has recently been approved for melanoma treatment. Here, by exome sequencing melanoma samples, Shi and colleagues show that B-RAF is amplified in tumours that have acquired resistance to the B-RAF inhibitor vemurafenib.

    • Hubing Shi
    • Gatien Moriceau
    • Roger S. Lo
    Research
    Nature Communications
    Volume: 3, P: 1-8

  • Although clinical trials have shown that RAF inhibitors prolong the survival of patients with BRAF-mutant melanoma, resistance inevitably develops; resistance is shown here to be frequently mediated by the expression of splicing variants of mutant BRAF.

    • Poulikos I. Poulikakos
    • Yogindra Persaud
    • David B. Solit
    Research
    Nature
    Volume: 480, P: 387-390

  • Genomic analyses in a rapid autopsy cohort study of patients with melanoma identify the genetic and transcriptomic landscape of melanoma with acquired resistance to MAPK inhibitor and immune checkpoint blockade therapies, providing insights for the potential improvement of therapeutic strategies.

    • Sixue Liu
    • Prashanthi Dharanipragada
    • Roger S. Lo
    ResearchOpen Access
    Nature Medicine
    Volume: 29, P: 1123-1134

  • Although loss-of-function p53 alterations are widespread in many tumors, melanomas typically do not harbor TP53 mutations. This report uncovers upregulation of MDM4 as a frequent trait of melanomas that contributes to tumorigenesis by inactivating p53 signaling. MDM4 is required for growth and survival of melanoma cell lines, and compounds that can target MDM4 are effective against melanoma in vivo and against tumors resistant to BRAF-targeted therapy in vitro.

    • Agnieszka Gembarska
    • Flavie Luciani
    • Jean-Christophe Marine
    Research
    Nature Medicine
    Volume: 18, P: 1239-1247

  • CRISPR-CATCH is used to isolate extrachromosomal DNA (ecDNA) molecules containing oncogenes from human cancer cells. CRISPR-CATCH followed by nanopore sequencing allows for methylation profiling, highlighting differences from the native chromosomal loci.

    • King L. Hung
    • Jens Luebeck
    • Howard Y. Chang
    ResearchOpen Access
    Nature Genetics
    Volume: 54, P: 1746-1754